MX9805157A - Secretagogos de la hormona de crecimiento. - Google Patents

Secretagogos de la hormona de crecimiento.

Info

Publication number
MX9805157A
MX9805157A MX9805157A MX9805157A MX9805157A MX 9805157 A MX9805157 A MX 9805157A MX 9805157 A MX9805157 A MX 9805157A MX 9805157 A MX9805157 A MX 9805157A MX 9805157 A MX9805157 A MX 9805157A
Authority
MX
Mexico
Prior art keywords
growth hormone
compounds
useful
directed
accelerating
Prior art date
Application number
MX9805157A
Other languages
English (en)
Inventor
Philip A Carpino
Paul A Dasilva Jardine
Bruce A Lefker
John A Ragan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21737850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9805157(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MX9805157A publication Critical patent/MX9805157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cooling Or The Like Of Electrical Apparatus (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invencion se dirige a compuestos de formula (I), y las sales farmacéuticamente aceptables de los mismos, donde los substituyentes son tal como se describe en la Memoria Descriptiva, los cuales son secretagogos de la hormona del crecimiento y aumentan el nivel de hormona del crecimiento endogena; los compuestos de esta invencion son utiles para el tratamiento y prevencion de la osteoporosis, el fallo cardiaco congestivo, la debilidad asociada con el envejecimiento, la obesidad; acelerar la reparacion de las fracturas oseas, atenuar la respuesta catabolica de proteínas tras una operacion importante, reducir la caquexia y la pérdida de proteína debida a enfermedades cronicas, acelerar la curacion de heridas o acelerar la recuperacion de pacientes quemados o de pacientes que hayan sufrido cirugía mayor; mejorar la fuerza muscular, la movilidad, el mantenimiento del espesor de la piel, la homeostasis metabolica o la homeostasis renal; los compuestos de la presente invencion también son utiles en el tratamiento de la osteoporosis cuando se usan en combinacion con: un compuesto bisfosfonato tal como alendronato, estrogeno, Premarin y opcionalmente progesterona; un agonista o antagonista de estrogeno; o calcitonina, y composiciones farmacéuticas utiles para ello; además, la presente invencion se dirige a composiciones farmacéuticas utiles para aumentar la produccion o liberacion endogena de hormona del crecimiento en un humano u otro animal que comprenden una actividad efectiva de un compuesto de la presente invencion y un secretagogo de la hormona del crecimiento seleccionado de GHRP-6, Hexarelin, GHRP-1, factor de la liberacion de la hormona del crecimiento (GRF), IGF-1, IGF-2 o B-HT920; la invencion también se dirige a intermediosutiles en la preparacion de compuestos de formula I.
MX9805157A 1995-12-28 1998-06-24 Secretagogos de la hormona de crecimiento. MX9805157A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US946995P 1995-12-28 1995-12-28

Publications (1)

Publication Number Publication Date
MX9805157A true MX9805157A (es) 1998-10-31

Family

ID=21737850

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9805157A MX9805157A (es) 1995-12-28 1998-06-24 Secretagogos de la hormona de crecimiento.

Country Status (43)

Country Link
US (7) US6124264A (es)
EP (1) EP0869968B1 (es)
JP (2) JP3511382B2 (es)
KR (1) KR100320167B1 (es)
CN (1) CN1113895C (es)
AP (2) AP756A (es)
AR (2) AR004367A1 (es)
AT (1) ATE361314T1 (es)
AU (1) AU716934B2 (es)
BG (1) BG64055B1 (es)
BR (1) BR9612465B1 (es)
CA (1) CA2241725C (es)
CO (1) CO4480108A1 (es)
CZ (1) CZ293423B6 (es)
DE (1) DE69637063T2 (es)
DK (1) DK0869968T3 (es)
EG (1) EG24195A (es)
ES (1) ES2285715T3 (es)
GT (1) GT199600100A (es)
HN (1) HN1996000085A (es)
HR (1) HRP960618B1 (es)
HU (1) HUP9901246A3 (es)
IL (4) IL138910A0 (es)
IS (1) IS4758A (es)
MA (1) MA26415A1 (es)
MX (1) MX9805157A (es)
MY (1) MY135727A (es)
NO (1) NO325135B1 (es)
NZ (1) NZ322172A (es)
OA (1) OA10702A (es)
PE (1) PE30398A1 (es)
PL (1) PL186916B1 (es)
PT (1) PT869968E (es)
RS (1) RS49926B (es)
SA (1) SA97170581B1 (es)
SI (1) SI0869968T1 (es)
SK (1) SK285678B6 (es)
TN (1) TNSN96172A1 (es)
TR (1) TR199801233T2 (es)
TW (1) TW432073B (es)
UA (1) UA66754C2 (es)
WO (1) WO1997024369A1 (es)
ZA (1) ZA9610858B (es)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
NZ516696A (en) 1997-04-15 2003-08-29 Csir Pharmaceutical compositions having appetite suppressant activity
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
AU7445498A (en) 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6893877B2 (en) 1998-01-12 2005-05-17 Massachusetts Institute Of Technology Methods for screening substances in a microwell array
EP1047709B1 (en) 1998-01-16 2004-11-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6657063B1 (en) * 1998-04-30 2003-12-02 Pfizer Inc. Combinations of β3 agonists and growth hormone secretagogues
HUP0102236A3 (en) * 1998-06-03 2003-01-28 Pfizer Prod Inc 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors and pharmaceutical compositions containing them and their use
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
CA2335112A1 (en) * 1998-06-16 1999-12-23 Hua Zhu Ke Therapeutic combinations for musculoskeletal frailty
PE20000646A1 (es) * 1998-06-16 2000-08-05 Pfizer Prod Inc Terapia de combinacion para la fragilidad musculoesqueletica
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
EP1156808A2 (en) * 1998-09-02 2001-11-28 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
WO2000015273A1 (de) 1998-09-11 2000-03-23 Gerhard Schmidmaier Biologisch aktive implantate
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
US6380184B1 (en) 1998-10-28 2002-04-30 Bristol-Myers Squibb Co. Benzoazepines and analogs thereof useful as growth hormone secretagogues
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
SI1004583T1 (en) * 1998-11-23 2004-12-31 Pfizer Products Inc. Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
US6297380B1 (en) 1998-11-23 2001-10-02 Pfizer Inc. Process and intermediates for growth hormone secretagogues
EP1930021A3 (en) 1999-02-18 2008-06-18 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US6551996B1 (en) * 1999-07-26 2003-04-22 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CA2395996A1 (en) 1999-12-28 2001-07-05 Kaken Pharmaceutical Co., Ltd. Neuroprotective drug
US7332271B2 (en) * 2000-02-18 2008-02-19 Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
US20020151040A1 (en) * 2000-02-18 2002-10-17 Matthew O' Keefe Apparatus and methods for parallel processing of microvolume liquid reactions
EP1132388A3 (en) 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
AU2001259592B2 (en) 2000-05-11 2005-02-24 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
DOP2001000154A (es) * 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
EP1159964B1 (en) * 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
IL143690A0 (en) * 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942A0 (en) * 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
EP1181933A3 (en) * 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144468A0 (en) * 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
BR0113626A (pt) * 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
IL145540A0 (en) * 2000-09-28 2002-06-30 Pfizer Prod Inc Use of growth hormone secretagogues in conjunction with physical exercise
EP1330306A2 (en) * 2000-10-10 2003-07-30 BioTrove, Inc. Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
US20100261159A1 (en) 2000-10-10 2010-10-14 Robert Hess Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20030199514A1 (en) * 2002-03-27 2003-10-23 Fryburg David A. Methods for improving efficacy of treatment with growth hormone secretagogues
ES2266798T3 (es) * 2002-04-09 2007-03-01 Eli Lilly And Company Secretagodos de hormona de crecimiento.
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US8277753B2 (en) * 2002-08-23 2012-10-02 Life Technologies Corporation Microfluidic transfer pin
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
US20060094108A1 (en) * 2002-12-20 2006-05-04 Karl Yoder Thermal cycler for microfluidic array assays
WO2004074818A2 (en) * 2002-12-20 2004-09-02 Biotrove, Inc. Assay apparatus and method using microfluidic arrays
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004108120A1 (en) * 2003-06-11 2004-12-16 Pfizer Products Inc. Use of growth hormone secretagogues for treatment of fibromyalgia
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US7129561B2 (en) * 2003-11-19 2006-10-31 International Business Machines Corporation Tri-metal and dual-metal stacked inductors
CA2559171A1 (en) 2004-03-12 2005-09-29 Biotrove, Inc. Nanoliter array loading
US20050261332A1 (en) * 2004-04-02 2005-11-24 Distefano Peter Sulfonamides and uses thereof
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
WO2005097174A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
EP1778679A1 (en) 2004-07-28 2007-05-02 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
US20060105453A1 (en) * 2004-09-09 2006-05-18 Brenan Colin J Coating process for microfluidic sample arrays
KR20130048793A (ko) * 2004-08-12 2013-05-10 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을 촉진하는 방법
EP2389941A1 (en) 2004-08-18 2011-11-30 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
KR101397913B1 (ko) 2005-05-30 2014-05-26 엠에스디 가부시키가이샤 신규 피페리딘 유도체
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US8163770B2 (en) 2005-10-27 2012-04-24 Msd. K. K. Benzoxathiin derivative
KR101318127B1 (ko) 2005-11-10 2013-10-16 엠에스디 가부시키가이샤 아자 치환된 스피로 유도체
EP1967208A4 (en) * 2005-11-21 2009-09-02 Univ Miyazaki THERAPEUTIC AGENT FOR SKIN OR AGENT PROMOTING REGENERATION OF SKIN CONTAINING GHRELINE, AND DERIVATIVES THEREOF OR SUBSTANCE CAPABLE OF ACTING AS ACTIVE INGREDIENT ON GHS-R1a
US8273702B2 (en) * 2006-02-17 2012-09-25 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CU23592A1 (es) * 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
WO2007106385A2 (en) * 2006-03-10 2007-09-20 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
US8557776B2 (en) * 2006-09-08 2013-10-15 Bayer Pharma AG Compounds and methods for 18F labeled agents
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
BRPI0719956A2 (pt) * 2006-10-02 2014-04-29 Bayer Schering Pharma Ag Radiofluoração
US20080114055A1 (en) * 2006-11-10 2008-05-15 Zoltan Laboratories Llc Thioxanthone Compounds to Reverse Weight Loss
MX2009008574A (es) 2007-02-09 2009-12-09 Tranzyme Pharma Inc Moduladores del receptor de grelina macrociclicos y metodos para usar el mismo.
EA200901142A1 (ru) * 2007-03-01 2010-04-30 Байер Шеринг Фарма Акциенгезельшафт 18f фторбензоильные меченые биологически активные соединения в качестве диагностических визуализирующих средств, а также бензотриазол-1-илоксибензоильные, 2,5-(диоксопирролидин-1-илокси)бензоильные и триметиламмониобензоильные предшественники
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2168602A4 (en) * 2007-06-12 2014-10-29 Inst Pharm & Toxicology Amms LINEAR, PEGYLATED, SITE-SPECIFIC SALMON CALCITONIN DERIVATIVES
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
CN101981025A (zh) 2008-03-28 2011-02-23 万有制药株式会社 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EA201170624A1 (ru) 2008-10-30 2011-12-30 Мерк Шарп Энд Домэ Корп. Изоникотинамидные антагонисты рецепторов орексинов
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361912A1 (en) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
ES2615731T3 (es) 2010-02-26 2017-06-08 Raqualia Pharma Inc. Agonista del receptor de ghrelina para el tratamiento de caquexia
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
MX2013012259A (es) * 2011-04-21 2013-11-22 Theratechnologies Inc Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos.
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
JP2015517452A (ja) * 2012-05-25 2015-06-22 ラクオリア創薬株式会社 無酸症を治療するためのグレリン受容体アゴニスト
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR20150058345A (ko) 2012-09-27 2015-05-28 아라타나 세라퓨틱스, 인크. 식욕부진을 조절 화합물 조성물 및 이의 이용 방법
BR112015009107A2 (pt) 2012-10-24 2017-11-14 Daiichi Sankyo Co Ltd agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo
CA2898482A1 (en) 2013-02-22 2014-08-28 Linda L. Brockunier Antidiabetic bicyclic compounds
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2910123C (en) * 2013-05-28 2021-11-02 Raqualia Pharma Inc. Polymorph form of 2-amino-n-[2-(3a-(r)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro­pyrazolo[4,3-c]pyridin-5-yl)-1-(r)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide l-tartrate
CA2913737A1 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
KR102051433B1 (ko) * 2013-08-27 2020-01-08 (주)네오팜 근육 분화 촉진 및 근육 강화용 조성물 및 외용제
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
KR101980180B1 (ko) * 2014-08-05 2019-05-20 라퀄리아 파마 인코포레이티드 그렐린 수용체 작용제로서의 세린 유도체
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
WO2016067638A1 (en) * 2014-10-31 2016-05-06 Raqualia Pharma Inc. Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CN109320515A (zh) * 2018-11-22 2019-02-12 常州大学 一种Capromorelin手性中间体的不对称合成方法
EP3924058A1 (en) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO136251C (no) * 1971-05-11 1977-08-10 Sandoz Ag Analogifremgangsm}te for fremstilling av terapeutisk aktive pyridazin-derivater.
DE2221808C2 (de) * 1972-05-04 1985-06-20 Sandoz-Patent-GmbH, 7850 Lörrach Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel
IL107836A (en) * 1992-12-11 1998-01-04 Merck & Co Inc Spiro piperidines and homologues, their preparation and pharmaceutical preparations containing them
JP3670690B2 (ja) * 1993-10-04 2005-07-13 トーアエイヨー株式会社 ３−ピリダジノン誘導体、その製造法およびそれを含有する循環器官用剤
CA2173333A1 (en) * 1993-10-19 1995-04-27 Barry J. Gertz Combination of bisphosphonates and growth hormone secretagogues
BR9408019A (pt) * 1993-11-09 1997-08-26 Merck & Co Inc Composto composição util para aumentar a produção endógena ou a liberaçao de hormonio do crescimento em ser humano ou um animal e para o tratamento da osteoporose processos para aumentar os niveis de hormônio do crescimento em um ser humano ou um animal e a eficácia de alimentação promover o crescimento aumentar a produçao de leite e melhorar a qualidade da carcaça de gado para tratar ou previnir uma condição selecionada para tratar osteoporose e para preparar um composto
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5767118A (en) * 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
CA2211381C (en) * 1995-01-27 2009-05-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1996024580A1 (en) * 1995-02-09 1996-08-15 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU4534696A (en) * 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1997007117A1 (en) * 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamines as growth hormone secretagogues
CA2203428A1 (en) * 1995-08-21 1997-02-27 Philip Arthur Hipskind 2-acylaminopropanamides as growth hormone secretagogues
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Also Published As

Publication number Publication date
TW432073B (en) 2001-05-01
SK285678B6 (sk) 2007-06-07
US6124264A (en) 2000-09-26
AP756A (en) 1999-08-06
US6107306A (en) 2000-08-22
TNSN96172A1 (fr) 2005-03-15
CA2241725A1 (en) 1997-07-10
BG102533A (en) 1999-09-30
AU7585096A (en) 1997-07-28
US6278000B1 (en) 2001-08-21
US6306875B1 (en) 2001-10-23
RS49926B (sr) 2008-09-29
NO982991D0 (no) 1998-06-26
SI0869968T1 (sl) 2007-08-31
BR9612465A (pt) 1999-07-13
NZ322172A (en) 2000-08-25
AP9600881A0 (en) 1997-01-31
SK87498A3 (en) 1999-08-06
MA26415A1 (fr) 2004-12-20
HRP960618A2 (en) 1998-04-30
AR052506A2 (es) 2007-03-21
US20020049196A1 (en) 2002-04-25
CA2241725C (en) 2002-06-18
BG64055B1 (bg) 2003-11-28
PL186916B1 (pl) 2004-03-31
PL327634A1 (en) 1998-12-21
IL138910A0 (en) 2001-11-25
DE69637063D1 (de) 2007-06-14
NO325135B1 (no) 2008-02-04
AP860A (en) 1999-08-06
CZ199598A3 (cs) 1999-05-12
CZ293423B6 (cs) 2004-04-14
JPH11501945A (ja) 1999-02-16
MY135727A (en) 2008-06-30
ATE361314T1 (de) 2007-05-15
CN1113895C (zh) 2003-07-09
NO982991L (no) 1998-08-26
IL138909A0 (en) 2001-11-25
PT869968E (pt) 2007-07-11
ZA9610858B (en) 1998-06-23
IL124449A0 (en) 1998-12-06
IS4758A (is) 1998-05-26
JP3511382B2 (ja) 2004-03-29
HUP9901246A2 (hu) 1999-08-30
EG24195A (en) 2008-10-14
EP0869968B1 (en) 2007-05-02
GT199600100A (es) 1998-06-12
ES2285715T3 (es) 2007-11-16
SA97170581B1 (ar) 2006-03-15
KR100320167B1 (ko) 2003-11-14
YU70296A (en) 1999-11-22
AP9901555A0 (en) 1999-06-30
HN1996000085A (es) 1997-06-18
UA66754C2 (en) 2004-06-15
AR004367A1 (es) 1998-11-04
IL138911A (en) 2007-07-24
US6482825B2 (en) 2002-11-19
OA10702A (en) 2001-05-07
AU716934B2 (en) 2000-03-09
DK0869968T3 (da) 2007-09-10
CN1206422A (zh) 1999-01-27
JP2001213800A (ja) 2001-08-07
DE69637063T2 (de) 2008-02-07
US6313140B1 (en) 2001-11-06
US6110932A (en) 2000-08-29
HUP9901246A3 (en) 1999-11-29
BR9612465B1 (pt) 2010-08-10
IL138911A0 (en) 2001-11-25
IL124449A (en) 2004-06-01
EP0869968A1 (en) 1998-10-14
WO1997024369A1 (en) 1997-07-10
PE30398A1 (es) 1998-07-21
CO4480108A1 (es) 1997-07-09
KR19990076846A (ko) 1999-10-25
TR199801233T2 (xx) 1998-10-21
HRP960618B1 (en) 2007-12-31

Similar Documents

Publication Publication Date Title
MX9805157A (es) Secretagogos de la hormona de crecimiento.
AP9801270A0 (en) Dipeptide derivatives.
MXPA03006951A (es) Secretagogos de hormona del crecimiento.
DK1002802T3 (da) Dipeptidderivater som væksthormonsecerneringsfremkaldende stoffer
US6583114B2 (en) Fracture healing using pthrp analogs
US7226904B2 (en) Agents and methods for promoting bone growth
CN1314912A (zh) 一种用作生长激素促分泌素的取代二肽的酒石酸盐
EP0635270A1 (en) Parathyroid hormone and raloxifene for increasing bone mass
JPH06511233A (ja) 骨の形成を促進するための骨成長因子および骨吸収阻害剤
CZ20022048A3 (cs) Selektivní agonisty receptoru EP4 při léčení osteoporosy
BR0111591B1 (pt) Composto, composição farmacêutica, e, usos de um composto
US7034050B2 (en) Pseudopeptides growth hormone secretagogues
US6923968B2 (en) Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
US6211174B1 (en) Naphtho-fused lactams promote release of growth hormone
US6573291B2 (en) Method and use
WO2000074702A1 (en) Compositions for the treatment of the catabolic state of prolonged critical illness
Ehlers Recombinant human GHRH (1–44) NH2: clinical utility and therapeutic development program
WO1998053827A1 (en) Treatment of osteoporosis
WO2002057241A1 (en) 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES
EP1756142B1 (en) Pseudopeptides growth hormone secretagogues
JP2007502841A (ja) 成長ホルモンの２０ｋＤａ胎盤性変種を用いる体形成療法
WO2002056873A2 (en) 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues
Akgül et al. Impact of calcitonin on urinary excretion of prostaglandins during menopause
MXPA99012100A (es) Sal tartrato de un dipeptido sustituido

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights